Benzinga | Aug 3, 2021 08:12AM EDT

Alnylam Pharmaceuticals Q2 EPS $(1.30) Beats $(1.60) Estimate, Sales $220.55M Beat $193.18M Estimate

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported quarterly losses of $(1.30) per share which beat the analyst consensus estimate of $(1.60) by 18.75 percent. This is a 22.16 percent increase over losses of $(1.67) per share from the same period last year. The company reported quarterly sales of $220.55 million which beat the analyst consensus estimate of $193.18 million by 14.17 percent. This is a 112.15 percent increase over sales of $103.96 million the same period last year.